vs

Side-by-side financial comparison of Designer Brands Inc. (DBI) and Revvity (RVTY). Click either name above to swap in a different company.

Revvity is the larger business by last-quarter revenue ($772.1M vs $752.4M, roughly 1.0× Designer Brands Inc.). Revvity runs the higher net margin — 12.7% vs 2.4%, a 10.3% gap on every dollar of revenue. On growth, Revvity posted the faster year-over-year revenue change (5.9% vs -3.2%). Revvity produced more free cash flow last quarter ($161.8M vs $57.5M). Over the past eight quarters, Revvity's revenue compounded faster (9.0% CAGR vs -0.1%).

Designer Brands Inc. is an American company that sells designer and name brand shoes and fashion accessories. It owns the Designer Shoe Warehouse (DSW) store chain, and operates over 500 stores in the United States and an e-commerce website.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

DBI vs RVTY — Head-to-Head

Bigger by revenue
RVTY
RVTY
1.0× larger
RVTY
$772.1M
$752.4M
DBI
Growing faster (revenue YoY)
RVTY
RVTY
+9.0% gap
RVTY
5.9%
-3.2%
DBI
Higher net margin
RVTY
RVTY
10.3% more per $
RVTY
12.7%
2.4%
DBI
More free cash flow
RVTY
RVTY
$104.3M more FCF
RVTY
$161.8M
$57.5M
DBI
Faster 2-yr revenue CAGR
RVTY
RVTY
Annualised
RVTY
9.0%
-0.1%
DBI

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
DBI
DBI
RVTY
RVTY
Revenue
$752.4M
$772.1M
Net Profit
$18.2M
$98.4M
Gross Margin
45.1%
Operating Margin
5.7%
14.5%
Net Margin
2.4%
12.7%
Revenue YoY
-3.2%
5.9%
Net Profit YoY
40.0%
3.9%
EPS (diluted)
$0.35
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DBI
DBI
RVTY
RVTY
Q4 25
$752.4M
$772.1M
Q3 25
$739.8M
$698.9M
Q2 25
$686.9M
$720.3M
Q1 25
$713.6M
$664.8M
Q4 24
$777.2M
$729.4M
Q3 24
$771.9M
$684.0M
Q2 24
$746.6M
$691.7M
Q1 24
$754.3M
$649.9M
Net Profit
DBI
DBI
RVTY
RVTY
Q4 25
$18.2M
$98.4M
Q3 25
$10.8M
$46.7M
Q2 25
$-17.4M
$53.9M
Q1 25
$-38.2M
$42.2M
Q4 24
$13.0M
$94.6M
Q3 24
$13.8M
$94.4M
Q2 24
$783.0K
$55.4M
Q1 24
$-29.6M
$26.0M
Gross Margin
DBI
DBI
RVTY
RVTY
Q4 25
45.1%
Q3 25
43.7%
53.6%
Q2 25
43.0%
54.5%
Q1 25
75.7%
56.5%
Q4 24
43.0%
Q3 24
44.0%
56.3%
Q2 24
44.2%
55.7%
Q1 24
38.8%
54.6%
Operating Margin
DBI
DBI
RVTY
RVTY
Q4 25
5.7%
14.5%
Q3 25
3.6%
11.7%
Q2 25
-1.1%
12.6%
Q1 25
-3.6%
10.9%
Q4 24
2.9%
16.3%
Q3 24
3.7%
14.3%
Q2 24
1.3%
12.4%
Q1 24
-4.8%
6.8%
Net Margin
DBI
DBI
RVTY
RVTY
Q4 25
2.4%
12.7%
Q3 25
1.5%
6.7%
Q2 25
-2.5%
7.5%
Q1 25
-5.3%
6.4%
Q4 24
1.7%
13.0%
Q3 24
1.8%
13.8%
Q2 24
0.1%
8.0%
Q1 24
-3.9%
4.0%
EPS (diluted)
DBI
DBI
RVTY
RVTY
Q4 25
$0.35
$0.86
Q3 25
$0.22
$0.40
Q2 25
$-0.36
$0.46
Q1 25
$-0.69
$0.35
Q4 24
$0.24
$0.77
Q3 24
$0.24
$0.77
Q2 24
$0.01
$0.45
Q1 24
$-899.54
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DBI
DBI
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$51.4M
$919.9M
Total DebtLower is stronger
$463.1M
Stockholders' EquityBook value
$298.6M
$7.3B
Total Assets
$2.1B
$12.2B
Debt / EquityLower = less leverage
1.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DBI
DBI
RVTY
RVTY
Q4 25
$51.4M
$919.9M
Q3 25
$44.9M
$931.4M
Q2 25
$46.0M
$991.8M
Q1 25
$44.8M
$1.1B
Q4 24
$36.2M
$1.2B
Q3 24
$38.8M
$1.2B
Q2 24
$43.4M
$2.0B
Q1 24
$49.2M
$1.7B
Total Debt
DBI
DBI
RVTY
RVTY
Q4 25
$463.1M
Q3 25
$509.6M
Q2 25
$516.2M
Q1 25
$484.3M
Q4 24
$529.6M
Q3 24
$459.0M
Q2 24
$469.3M
Q1 24
$420.3M
Stockholders' Equity
DBI
DBI
RVTY
RVTY
Q4 25
$298.6M
$7.3B
Q3 25
$280.8M
$7.4B
Q2 25
$266.9M
$7.6B
Q1 25
$278.5M
$7.6B
Q4 24
$318.5M
$7.7B
Q3 24
$355.5M
$7.9B
Q2 24
$358.5M
$7.9B
Q1 24
$359.2M
$7.8B
Total Assets
DBI
DBI
RVTY
RVTY
Q4 25
$2.1B
$12.2B
Q3 25
$2.1B
$12.1B
Q2 25
$2.1B
$12.4B
Q1 25
$2.0B
$12.4B
Q4 24
$2.1B
$12.4B
Q3 24
$2.1B
$12.8B
Q2 24
$2.2B
$13.4B
Q1 24
$2.1B
$13.4B
Debt / Equity
DBI
DBI
RVTY
RVTY
Q4 25
1.55×
Q3 25
1.81×
Q2 25
1.93×
Q1 25
1.74×
Q4 24
1.66×
Q3 24
1.29×
Q2 24
1.31×
Q1 24
1.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DBI
DBI
RVTY
RVTY
Operating Cash FlowLast quarter
$66.5M
$182.0M
Free Cash FlowOCF − Capex
$57.5M
$161.8M
FCF MarginFCF / Revenue
7.6%
21.0%
Capex IntensityCapex / Revenue
1.2%
2.6%
Cash ConversionOCF / Net Profit
3.65×
1.85×
TTM Free Cash FlowTrailing 4 quarters
$99.9M
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DBI
DBI
RVTY
RVTY
Q4 25
$66.5M
$182.0M
Q3 25
$21.4M
$138.5M
Q2 25
$-20.4M
$134.3M
Q1 25
$70.1M
$128.2M
Q4 24
$-9.8M
$174.2M
Q3 24
$41.6M
$147.9M
Q2 24
$-19.7M
$158.6M
Q1 24
$-40.1M
$147.6M
Free Cash Flow
DBI
DBI
RVTY
RVTY
Q4 25
$57.5M
$161.8M
Q3 25
$11.9M
$120.0M
Q2 25
$-27.6M
$115.5M
Q1 25
$58.1M
$112.2M
Q4 24
$-19.2M
$149.8M
Q3 24
$28.0M
$125.6M
Q2 24
$-35.6M
$136.6M
Q1 24
$-52.8M
$129.7M
FCF Margin
DBI
DBI
RVTY
RVTY
Q4 25
7.6%
21.0%
Q3 25
1.6%
17.2%
Q2 25
-4.0%
16.0%
Q1 25
8.1%
16.9%
Q4 24
-2.5%
20.5%
Q3 24
3.6%
18.4%
Q2 24
-4.8%
19.7%
Q1 24
-7.0%
20.0%
Capex Intensity
DBI
DBI
RVTY
RVTY
Q4 25
1.2%
2.6%
Q3 25
1.3%
2.6%
Q2 25
1.1%
2.6%
Q1 25
1.7%
2.4%
Q4 24
1.2%
3.4%
Q3 24
1.8%
3.3%
Q2 24
2.1%
3.2%
Q1 24
1.7%
2.7%
Cash Conversion
DBI
DBI
RVTY
RVTY
Q4 25
3.65×
1.85×
Q3 25
1.98×
2.97×
Q2 25
2.49×
Q1 25
3.03×
Q4 24
-0.75×
1.84×
Q3 24
3.01×
1.57×
Q2 24
-25.13×
2.87×
Q1 24
5.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DBI
DBI

Womens$280.7M37%
Athletic Footwear$188.6M25%
Wholesale$89.8M12%
Canada Retail Segment$77.3M10%
Mens$76.1M10%
Kids$24.2M3%
Commission Income$10.8M1%
Directto Consumer$1.3M0%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons